GSK plc (LON:GSK) Declares GBX 15 Dividend

GSK plc (LON:GSK) declared a dividend on Wednesday, October 30th,Upcoming Dividends.Co.Uk reports. Shareholders of record on Thursday, November 14th will be given a dividend of GBX 15 ($0.19) per share on Thursday, January 9th. This represents a yield of 1.03%. The ex-dividend date is Thursday, November 14th. The official announcement can be seen at this link.

GSK Stock Performance

Shares of GSK stock opened at GBX 1,359.97 ($17.50) on Wednesday. GSK has a 52 week low of GBX 1,352.86 ($17.41) and a 52 week high of GBX 1,823.50 ($23.47). The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. The business has a 50 day moving average price of GBX 1,507.18 and a 200-day moving average price of GBX 1,581.86. The company has a market cap of £55.49 billion, a PE ratio of 1,204.87, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

Insider Activity

In related news, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the stock in a transaction on Monday, September 23rd. The shares were acquired at an average price of GBX 2,051 ($26.39) per share, with a total value of £9,147.46 ($11,771.28). In other news, insider Elizabeth (Liz) McKee Anderson bought 446 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was acquired at an average cost of GBX 2,051 ($26.39) per share, with a total value of £9,147.46 ($11,771.28). Also, insider Jonathan Symonds purchased 7,150 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of GBX 1,394 ($17.94) per share, for a total transaction of £99,671 ($128,260.20). Insiders acquired a total of 7,604 shares of company stock valued at $10,893,038 in the last ninety days. 1.61% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on GSK. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research report on Monday, July 29th. Berenberg Bank reiterated a “buy” rating and issued a GBX 1,820 ($23.42) target price on shares of GSK in a research note on Tuesday, September 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,850 ($23.81) price target on shares of GSK in a research report on Tuesday, September 3rd. Finally, Shore Capital reaffirmed a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, GSK has an average rating of “Moderate Buy” and an average target price of GBX 1,842.50 ($23.71).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.